Introduction
============

The opportunistic yeast *Candida glabrata* is the second most common cause of candidemia and invasive candidiasis (IC) in many countries ([@B5]; [@B26]; [@B39]; [@B15]). Its clinical importance as a species lies in its reduced susceptibility to azole antifungal agents; more recently, resistance to the echinocandins as well as resistance to both these drug classes ([@B40]; [@B52]; [@B45]). This has prompted much investigation of the epidemiology and biological properties of *C. glabrata* infections ([@B48]).

Because the prevalence of *C. glabrata* candidiasis and drug resistance rates varies both between and within geographical region, local epidemiological data are essential to inform management ([@B40]; [@B26]). The reasons for this variation are uncertain but likely include prior exposure to azoles, patient factors and geographic location-specific determinants. Fungus-specific factors such as genetic strain variation within species are also pertinent. Delineation of intraspecies variation is useful not only to elucidate the molecular epidemiology of *C. glabrata* infections but also to assess potential transmission routes, biological niches and population structure. Yet relatively little is known about the genomic variation between isolates from different regions or the clinical significance of such differences.

Genetic typing methods e.g., pulsed-field gel electrophoresis, microsatellite analysis and multilocus sequence typing (MLST) have been used to determine genetic relatedness of *C. glabrata* ([@B22]; [@B33]; [@B1]). In particular, the use of a standardized 6-locus MLST system ([@B22]) has improved discrimination between isolates with good reproducibility and portability of data via internet-accessible databases. Major findings from MLST analyses highlight that despite description of a broad range of MLST sequence types (STs), *C. glabrata* appears to be highly clonal with infrequent emergence of novel STs, which may be restricted to various geographical regions ([@B35]; [@B30]; [@B3]). This observed clonality however, may be fluid with temporal shifts of the major *C. glabrata* subtypes documented over time in one study ([@B34]). More discriminatory methods for pathogen discrimination such as next generation sequencing (NGS) offer new insights into *C. glabrata* genetics including its molecular epidemiology and population dynamics. Global spread of previously isolated populations was inferred from genomic data in a recent study ([@B13]). In addition, NGS has been utilized to elucidate mechanisms of drug resistance in this species from the diagnostic laboratory perspective ([@B46]; [@B9]).

In Australia, we observed a 1.7-fold increase in the proportion of *Candida* bloodstream infections caused by *C. glabrata* over a decade (2004--2006 vs. 2014--2015) ([@B16]; [@B15]). Our laboratory is increasingly using whole genome sequencing (WGS) approaches, in line with international trends, in public health practice and investigations of nosocomial infections ([@B8]). Here we applied WGS to investigate the genetic diversity of Australian *C. glabrata* strains across more than a decade and sought associations between the frequency of sequence types and two time periods and with drug susceptibility to fluconazole.

Materials and Methods {#s1}
=====================

Ethics Statement
----------------

All isolates were obtained from our culture collection spanning 10--20 years and represent previous surveillance isolates for which research ethics approval had been obtained. The present study was a laboratory-based epidemiological study. No identifiable patient data or medical records were accessed.

Isolates and Identification
---------------------------

Fifty-two *C. glabrata* (sensu stricto) isolates were studied. These comprised *C. glabrata* ATCC 90030 and 51 *C. glabrata* isolates from Australia obtained through the culture collection at the Clinical Mycology Laboratory, Westmead Hospital and the Molecular Mycology Research Laboratory, Westmead Millennium Institute for Medical Research, Sydney. With the exception of two isolates recovered from the same patient 3 weeks apart, all isolates represented single patient episodes of IC. The majority (\>90%) of isolates were from the jurisdictions of New South Wales and Victoria. All isolates were re-confirmed as *C. glabrata* sensu stricto by matrix-assisted laser desorption ionization-time of flight technique (MALDI-TOF MS) supplemented by ITS sequencing as required ([@B50]).

Susceptibility Testing
----------------------

Susceptibility to antifungal agents were determined using the Sensititre^®^YeastOne^TM^ YO10 methodology (TREK Diagnostics, Cleveland, OH, United States) according to Clinical and Laboratory Standards Institute (CLSI) methodology ([@B18]). *Candida parapsilosis* ATCC 22019 and *Candida krusei* ATCC 6258 were the quality control strains. MIC values were interpreted according to CLSI M60 guidelines for fluconazole and the echinocandins ([@B17]); where there are no clinical breakpoints (CBPs) (for voriconazole, posaconazole and amphotericin B), species-specific epidemiological cut-off values (ECVs) defined isolates as wild-type (WT) or non-WT ([@B19]). There are neither CBPs or ECVs for 5-fluorocytosine.

DNA Extraction and Library Preparation for Whole Genome Sequencing
------------------------------------------------------------------

*Candida glabrata* ATCC 90030 and the 51 clinical isolates were subcultured on Sabouraud's dextrose agar for 48 h at 35°C prior to testing to ensure purity. Genomic DNA was extracted using the Wizard^®^Genomic DNA Purification kit (Promega, Alexandria, NSW, Australia) and the concentration was quantified by Quant-iT^TM^ PicoGreen^®^dsDNA Assay Kit (Life Technologies, Mulgrave, VIC, Australia). The Nextera XT kit (Illumina, San Diego, CA, United States) was used to construct genomic libraries. Tagmentation, PCR amplification and cleanup, library normalization and pooling, and sequencing on the NextSeq 500 platform (Illumina) were carried out with 2 X 150-bp paired-end chemistry as previously described ([@B10]).

Whole Genome Sequencing Data Analysis
-------------------------------------

Sequence reads were deposited in the NCBI Sequence Read Archive (SRA: project number PRJNA480138) and were mapped against the reference genome of *C. glabrata* CBS138 (GenBank Accession 4 No. GCA_0002545.2^[1](#fn01){ref-type="fn"}^).

Obtained sequence reads were mapped to each chromosome independently (using *C glabrata* CBS 138 chromosomes A to M as the reference) employing Stampy v1.0.23 ([@B36]) with pre-BWA alignment. Analysis of the mitochondria was not included. Variants were called using FreeBayes v1.1.0-dirty and filtered for read depth (minimum 20), read base quality (minimum Phred score 30), mapping quality (minimum 30) and proportion of reads supporting the variant (\>0.9). All indels were excluded from the mapping-based analysis. An aligned mapped file for each chromosome was constructed for all isolates using an in-house script. All probable recombination events were identified using Gubbins ([@B20]) and subsequently masked prior to concatenating all chromosome sequences into a single SNP alignment.

To infer the phylogenetic relationship of the Australian isolates, the best-fitting substitution model (TVM+F+ASC+R2) was selected with the Bayesian Information Criterion using ModelFinder implemented in IQ-Tree v.1.6.2 ([@B38]; [@B32]). A maximum likelihood tree was then reconstructed using IQ-Tree using 1000 ultrafast bootstrap replicates ([@B29]).

To place our data into global context, all 38 publicly available *C. glabrata* Illumina short read sequence data from seven countries other than Australia were downloaded and included in the analysis ([@B27]; [@B13]; Table [2](#T2){ref-type="table"}). A network approach using SplitsTree4 ([@B31]) was employed to examine the relationships between our isolates and the isolates from other countries.

Single Polynucleotide Polymorphism of Genes Associated With Antifungal Resistance
---------------------------------------------------------------------------------

All SNPs in genes known for their role in drug resistance in *C. glabrata* ([@B43]; [@B7]; [@B4]) were manually curated in CLC Genomics Workbench (CLC Bio version 7.0, Arrhus, Denmark) with only non-synonymous SNPs reported. Genes examined included *FKS1, FKS2, FKS3* (for echinocandin resistance) *FCY1, FCY2, CgFPS1, CgFPS2* (5-fluorocytosine resistance), *ERG9, ERG11, CgCDR1*, and Cg*PDR1* (azole resistance) and *MSH2* (for multi-drug resistance). Only non-synonymous SNPs with a minimum read depth coverage of 20, defined as high-quality (hq), were included in the analysis.

MLST Sequence Types and Principal Component Analysis
----------------------------------------------------

*In silico* MLST sequence types (STs), inferred from whole genome sequence data (genome types) were obtained from assembled contigs using SPAdes v3.1.1.1 ([@B6]) and MLST software ([@B44], T^[2](#fn02){ref-type="fn"}^). All obtained STs were subsequently confirmed using a read based approach implemented through SRST2. Four novel *C. glabrata* MLST types (See Results) were submitted to the *C. glabrata* MLST database (Dr. Andrew Dodgson^[3](#fn03){ref-type="fn"}^ accessed September 11, 2018; and now Professor Oliver Bader, accessed November 5, 2018), and designated as ST123, ST124, ST126, and ST127. Clustering of isolates by genetic similarity according to time of isolation (2002--2004 vs. 2010--2017) and drug susceptibility (susceptible-dose-dependent (S-DD) or resistant (R) to fluconazole ([@B17])) was examined by Principal Component Analysis (PCA). PCA was based on a pairwise SNP distance matrix calculated under the K80 model with pairwise deletion, using the native *stats* R v3.4.1 package ([@B41]), and visualized with ggplot2 ([@B51]).

Results
=======

Of 51 Australian clinical isolates, 49 (94%) were cultured from blood. Thirteen (25%) isolates were from the time period 2002--2004, and 38 (75%) from, 2010--2017 (Table [1](#T1){ref-type="table"}).

###### 

*Candida glabrata* isolates, Australia: year of isolation, body site, sequence types and *in vitro* susceptibility to five antifungal agents.

  Isolate ID   Year isolation   Body site    ST      MIC μg/ml                          
  ------------ ---------------- ------------ ------- ----------- ------ ------- ------- -------
  ATCC 90030   NA               Blood        ST10    8           0.5    1       1       0.06
  WM_04.242    2002             Blood        ST7     32          0.5    NA      0.25    0.06
  WM_03.308    2003             Blood        ST7     8           0.25   0.125   0.125   0.008
  WM_03.419    2003             Blood        ST83    128^∗^      2      1       1       0.008
  WM_03.449    2003             Blood        ST26    64^∗^       1      0.5     0.25    0.25
  WM_03.450    2003             Blood        ST83    32          0.5    0.5     0.06    0.25
  WM_03.698    2003             Blood        ST7     32          1      0.5     0.06    0.25
  WM_03.707    2003             Blood        ST83    16          0.25   1       1       0.12
  WM_04.113    2003             Blood        ST123   128^∗^      2      2       0.125   0.125
  WM_04.387    2003             Blood        ST7     32          0.5    NA      0.25    0.25
  WM_04.194    2004             Blood        ST3     4           0.25   NA      1       0.25
  WM_05.155    2004             Blood        ST126   16          0.5    0.5     0.25    0.03
  WM_05.111    2004             Blood        ST55    32          1      NA      0.25    1
  WM_05.113    2004             Blood        ST18    64^∗^       1      NA      0.25    0.06
  WM_18.26     2010             Blood        ST10    8           0.12   0.5     2       \>8
  WM_18.24     2012             Blood        ST16    4           0.06   0.25    0.5     8
  WM_18.30     2014             Blood        ST3     16          0.5    1       1       0.25
  WM_18.31     2014             Blood        ST45    1           0.06   0.12    0.5     0.03
  WM_18.33     2014             Blood        ST7     128^∗^      2      \>8     0.5     0.06
  WM_18.36     2014             Blood        ST36    8           0.25   1       1       0.12
  WM_18.39     2014             Blood        ST83    2           0.03   0.06    0.5     0.06
  WM_18.40     2014             Blood        ST46    128^∗^      2      \>8     1       0.06
  WM_18.41     2014             Blood        ST123   8           0.25   1       0.5     0.12
  WM_18.42     2014             Blood        ST123   256^∗^      8      1       0.25    0.25
  WM_18.43     2014             Blood        ST83    8           0.25   1       1       0.06
  WM_18.44     2014             Blood        ST3     16          0.5    2       1       0.06
  WM_18.45     2014             Blood        ST127   16          0.25   1       0.5     0.06
  WM_18.34     2015             Blood        ST3     16          0.5    1       1       0.06
  WM_18.35     2015             Blood        ST3     4           0.12   0.25    0.5     0.03
  WM_18.37     2015             Blood        ST22    16          0.25   1       0.5     0.12
  WM_18.38     2015             Blood        ST6     8           0.25   1       1       0.25
  WM_18.47     2015             Blood        ST46    16          0.25   0.5     1       0.25
  WM_18.48     2015             Blood        ST83    32          1      2       1       0.06
  WM_18.27     2015             Blood        ST26    256^∗^      8      \>8     1       0.12
  WM_18.29     2015             Body fluid   ST10    4           0.5    0.5     0.5     0.06
  WM_18.49     2017             Blood        ST26    256^∗^      2      \>8     0.5     0.12
  WM_18.50     2017             Blood        ST59    8           0.25   1       1       0.06
  WM_18.51     2017             Blood        ST46    128^∗^      2      \>8     1       0.06
  WM_18.52     2017             Body fluid   ST16    4           0.12   0.5     0.25    0.12
  WM_18.53     2017             Blood        ST123   128^∗^      4      \>8     1       0.12
  WM_18.54     2017             Blood        ST26    0.5         0.03   0.03    1       0.25
  WM_18.55     2017             Blood        ST3     8           0.25   1       1       0.25
  WM_18.56     2017             Blood        ST22    32          0.5    2       0.5     0.12
  WM_18.57     2017             Blood        ST16    8           0.5    2       0.5     0.12
  WM_18.59     2017             Blood        ST3     16          1      2       0.5     0.12
  WM_18.60     2017             Blood        ST3     8           0.5    1       0.5     0.12
  WM_18.62     2017             Blood        ST55    32          2      2       1       0.06
  WM_18.63     2017             Blood        ST8     2           0.12   0.25    0.5     2
  WM_18.64     2017             Blood        ST8     4           0.12   0.25    0.5     2
  WM_18.65     2017             Blood        ST83    64^∗^       1      2       0.5     0.12
  WM_18.66     2017             Blood        ST124   256^∗^      8      2       0.125   0.25
  WM_18.67     2017             Tissue       ST26    16          0.5    1       1       0.5
                                                                                        

ID, identification; MIC, minimum inhibitory concentration; NA, not available; ST, sequence type (refers to the MLST sequence type).

∗

Isolates that are classed as resistant to fluconazole (

Clinical and Laboratory Standards Institute \[CLSI\], 2017a

).

Susceptibility Data
-------------------

Table [1](#T1){ref-type="table"} summarizes the MIC values of the isolates against five antifungal agents. All clinical isolates tested had low MICs against 5-fluorocytosine (≤0.12 μg/ml) and WT MICs (\<2 μg/ml) against amphotericin B. Four (7.8%) isolates (strains WM_18.26, WM_18.24, WM_18.64, and WM_18.63) were resistant to caspofungin (MIC range 2 to \>8 μg/ml; Table [1](#T1){ref-type="table"}), and cross resistant to micafungin and anidulafungin (results not shown) ([@B17]). Thirteen isolates (Strains WM_03.419, WM_03.449, WM_04.113, WM_05.113, WM_18.33, WM_18.40, WM_18.27, WM_18.42, WM_18.49, WM_18.51, WM_18.53, WM_18.65, and WM_18.66) were classified as resistant to fluconazole with MICs of ≥ 64 ug/ml ([@B17]); all also had non-WT MICs to voriconazole whilst posaconazole MICs ranged from 2 to \>8 μg/ml (Table [1](#T1){ref-type="table"}). However, six additional isolates (strains WM_18.44, WM_18.48, WM_18.56, WM_18.57, WM_18.59, and WM_18.62) had non-WT MICs to voriconazole and posaconazole although were susceptible-dose dependent to fluconazole, and yet 11 other isolates had non-WT MICs only to voriconazole (Table [1](#T1){ref-type="table"}).

Sequence Analysis
-----------------

Overall, an average of 95% of sequencing reads were mapped to the *C. glabrata* reference genome with a median read depth coverage of 75-fold. After mapping to each reference chromosome independently, a number of recombination events were identified (range, *n* = 320--776, lowest for chromosome B and highest for chromosome I -- data not shown).

*In silico* MLST and Global Phylogeny
-------------------------------------

By WGS, there were 18 distinct STs defined based on the alleles from six genetic loci (*FKS, LEU2, NMT1, TRP1, UGP1, and URA3*) among 52 isolates (Table [1](#T1){ref-type="table"} and Supplementary Table [S1](#SM1){ref-type="supplementary-material"}), including four new STs (referred to as ST123, ST124, ST126, and ST127) not previously recognized by the *C. glabrata* MLST database (<https://pubmlst.org/cglabrata/> see Supplementary Table [S1](#SM1){ref-type="supplementary-material"} for the allele numbers of the new STs). Strain ATCC 90030 typed as ST10.

Of the known STs, the commonest ST amongst the Australian isolates was ST3 (8/51, 15.7% of isolates) followed by ST83 (7/51 and 13.7%), ST7 and ST26 (each *n* = 5, 9.8%). Collectively, these four STs were responsible for almost half (*n* = 25; 49%) of the isolates. The most common new ST was ST123 (*n* = 4 isolates). Eight (17.6%) STs (ST6, ST18, ST36, ST45, ST59, ST124, ST126, and ST127) were represented by only a single isolate (Table [1](#T1){ref-type="table"}). Despite a relatively small number of isolates sequenced, the number of ST types was considerable compared to previous studies suggesting a relatively high genetic diversity within Australian *C. glabrata* isolates. Three isolates cultured from body sites other than blood were of ST10, ST16 and ST26 (Table [1](#T1){ref-type="table"}). The two isolates from the same patient (WM_18.63 and WM_18.64) were both ST8.

In general, the whole genome data clustered broadly within determined MLST types but with greater intra-cluster resolution. The split tree network analysis (Figure [1](#F1){ref-type="fig"}) resolved isolates to at least nine terminal branches containing four or more isolates; many of these comprise multiple isolates clustering together, and with isolates representing disparate geographic locations. However, four branches comprised of Australian isolates only (Figure [1](#F1){ref-type="fig"}). To place local isolates into a more global perspective, the STs of isolates reported from seven other countries are shown in Table [2](#T2){ref-type="table"}. Certain STs were common to isolates from the regions studied herein e.g., ST3 (Belgium, France, Germany, United States, Australia), whilst others were either more restricted, or were more prevalent to one or two countries e.g., ST6 in Norway and France, ST8 in the United States and continental Europe. The two isolates from Taiwan showed new STs. Of note, isolates of ST19 were absent from Australia (vs. 4/12 US isolates; Table [2](#T2){ref-type="table"}).

![Unrooted network tree depicting the association between Australian *Candida glabrata* isolates and international isolates from seven countries based on their whole genome sequences. All clusters in the tree have been represented by different sequence types (STs) except Norway 5, Norway 6, Taiwan 1 and Taiwan 2 which have previously unassigned (new) STs. New sequence types (STs) from Australia are ST123, ST124, ST126 and ST127. Isolates representing a particular ST in branches, which contain multiple STs, are put in circles. The colors depict isolates from different countries: Black, Australia; Green, Belgium; Blue, France; Brown, Germany; Purple, Italy; Pink, Norway; Yellow, Taiwan; Red, United States. The Australian isolates have names starting with WM\_ and the international isolates where named according to the country of origin, all followed by a numerical scheme. For isolates from same country in a cluster, the country name was followed by numerical identities of the isolates separated by commas. For example, in ST7 cluster, WM_18.33, 03.308,689, 04.242,387 (where 18, 03 and 04 are years of isolation followed by isolate number).](fmicb-09-02946-g001){#F1}

###### 

*Candida glabrata* isolates from countries other than Australia with known multi-locus sequence types as a comparison with sequence types of Australian isolates.

  Isolate ID^∗^   SRA Run ID   Country         Body site   Sequence Type
  --------------- ------------ --------------- ----------- ---------------
  Belgium1        SRR5239784   Belgium         Mouth       ST65
  Belgium2        SRR5239783   Belgium         Stool       ST65
  Belgium3        SRR5239781   Belgium         Stool       ST19
  Belgium4        SRR5239776   Belgium         Stool       ST7
  Belgium5        SRR5239782   Belgium         Mouth       ST19
  Belgium6        SRR5239756   Belgium         Mouth       ST3
  France1         SRR5239754   France          Blood       ST3
  France2         SRR5239767   France          Blood       ST22
  France3         SRR5239764   France          Blood       ST6
  France4         SRR5239768   France          Blood       ST22
  France5         SRR5239755   France          Blood       ST3
  France6         SRR5239765   France          Blood       ST10
  France7         SRR5239766   France          Stool       ST22
  France8         SRR5239773   France          Blood       ST2
  France9         SRR5239758   France          Blood       ST8
  Germany1        SRR5239759   France          Stool       ST3
  Italy1          SRR5239769   Italy           Blood       ST22
  Italy2          SRR5239770   Italy           Blood       ST8
  Norway1         SRR2982714   Norway          Blood       ST6
  Norway2         SRR2982715   Norway          Blood       ST6
  Norway3         SRR2982716   Norway          Blood       ST6
  Norway4         SRR2982717   Norway          Blood       ST6
  Norway5         SRR2982718   Norway          Blood       NEW ST
  Norway6         SRR2982719   Norway          Blood       NEW ST
  Taiwan1         SRR5239763   Taiwan          Mouth       NEW ST
  Taiwan2         SRR5239762   Taiwan          Mouth       NEW ST
  USA1            SRR5239757   United States   Blood       ST3
  USA2            SRR5239772   United States   Blood       ST2
  USA3            SRR5239774   United States   Blood       ST8
  USA4            SRR5239753   United States   Blood       ST8
  USA5            SRR5239761   United States   Blood       ST3
  USA6            SRR5239779   United States   Blood       ST19
  USA7            SRR5239777   United States   Blood       ST19
  USA8            SRR5239760   United States   Blood       ST3
  USA9            SRR5239778   United States   Blood       ST19
  USA10           SRR5239775   United States   Blood       ST7
  USA11           SRR5239771   United States   Blood       ST8
  USA12           SRR5239780   United States   Blood       ST19
                                                           

ID, identification; ST, sequence type; USA, United States of America.

∗

NEW ST: Sequence type reported as novel (

Carrete et al., 2018

).

Genomic Similarity According to Period of Isolation and Susceptibility to Fluconazole
-------------------------------------------------------------------------------------

On analysis of the sequenced genomes by PCA, there was no temporal association between the two periods of isolation (2002--2004 and 2010--2017) and genomic similarity (as represented by ST distribution), or between genomic similarity and fluconazole susceptibility as measured by MICs (fluconazole S-DD: *n* = 39 isolates vs. fluconazole-resistant: *n* = 12) (Figures [2A,B](#F2){ref-type="fig"}).

![Principle component analysis (PCA) of *Candida glabrata* genomic SNP distances following masking of recombination and **(A)** phenotypic fluconazole susceptibility or **(B)** period of isolation.](fmicb-09-02946-g002){#F2}

The phylogenetic relationship of the 51 Australian isolates was also reconstructed with high bootstrap support (Figure [3](#F3){ref-type="fig"}). There was no association between drug susceptibility to fluconazole, voriconazole, posaconazole or caspofungin (results were similar for anidulafungin and micafungin) or resistance, and phylogenetic clustering. Rather the analysis illustrated that resistance or non-WT MICs emerged at several time points along the phylogeny.

![Maximum likelihood phylogeny of Australian *Candida glabrata* isolates. Bootstrap support values of less than 100 are indicated at the corresponding nodes. Sequence types (STs) and minimum inhibitory concentrations (MICs) for fluconazole (FLU), voriconazole (VOR), posaconazole (POS) and caspofungin (CAS) of each isolate is indicated to the right of the tree. Isolates with MIC values that are classed as "resistant" or as "non-wild type" are colored in red.](fmicb-09-02946-g003){#F3}

Analysis for SNPS Related to Drug Resistance and Their Relationship to STs
--------------------------------------------------------------------------

Of two isolates with caspofungin MICs of ≥ 8 μg/ml, one (strain WM_18.24; ST16) contained the *FKS1* mutation leading to the amino acid substitution Ser629Pro, whilst strain WM_18.26 (ST10) harbored the *FKS2* mutation Ser663Pro. There were no other SNPs in any of *FKS1, FKS2* or *FKS3* in both strains. Isolates WM_18.63, and WM-18.64 (both ST8) recovered from the same patient harbored the *FKS1* mutation Ser629Pro as well as a *FKS2* mutation Glu784Gly. The Glu784Gly mutation was not present in any echinocandin susceptible isolates. Other SNPs were present in *FKS1* (Gly14Ser) and *FKS2* (Thr926Pro) but only in isolates of ST3. Several SNPs in *FKS3* (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}) were present in both echinocandin-susceptible and echinocandin-resistant isolates.

The presence of SNPs in genes linked to 5-fluorocytosine resistance e.g., *CgFPS1, CgFPS2* and *CgFCY1* and *CgFCY2* broadly, varied with ST with no SNPs observed in isolates of ST6, ST22, ST55, ST59 and ST123 (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). Fluconazole-resistant isolates (Table [1](#T1){ref-type="table"}) in general harbored mutations in *CgPDR1* and to a lesser extent in *CgCDR1*, but overall, SNPs in these genes and in other efflux pump genes, *CgFLR1* and *CgSNQ2* (data not shown) were also present in azole-susceptible/WT isolates (Supplementary Table [S2](#SM1){ref-type="supplementary-material"}). However, although no particular SNP was definitively linked to the resistance phenotype, 5/13 fluconazole-resistant isolates harbored Pdr1 amino acid substitutions in the region beyond the first 200--250 amino acids with no fluconazole-susceptible isolate containing such changes. In addition, 2/6 isolates with non-WT MICs to voriconazole and posaconazole (strains WM_18.48 and WM\_ 18.62; fluconazole MIC both 32 μg/ml) also harbored mutations resulting in amino acid substitutions outside this region. Conversely, substitutions within the first 250 amino acid positions in Pdr1 were common to both azole resistant and susceptible isolates (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). Eight fluconazole resistant isolates however, did not demonstrate a *PDR1* mutation. Isolates exhibiting pan-azole resistance, or which had non-WT MICs also had mutation in *CgCDR1* His58Tyr (6/10 isolates), but the last was also present in azole-susceptible isolates.

SNPs occurred in isolates of diverse ST. There were no SNPs in *ERG11* and the few SNPs observed in *ERG9* were predominantly in isolates of ST3 and ST26.

SNPs in the *MSH2* gene were observed in 19 of 51 (37%) isolates with three main locations of mutations -- Val239Leu (9 isolates), Glu456Asp (7 isolates) and Leu269Phe (3 isolates), with two isolates (strains WM_18.63 and WM_18.64) having two mutations at Val239Leu and Ala942Thr (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). The same *MSH2* mutations were found in azole susceptible as well as azole-resistant/non-WT isolates. Overall, SNPs were identified in isolates of diverse STs including in isolates of the new STs, ST123 and ST127 (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). Whilst the mutation Glu456Asp was found in isolates of 5 different STs and that of Val239Leu in 4 different STs, the Leu269Phe mutation was found only in isolates of ST16. The combination of Val239Leu and Ala942Thr were only identified in ST8 isolates, both of which were pan-echinocandin resistant.

Discussion
==========

Understanding the genomic diversity of *C. glabrata* and its antifungal susceptibility patterns is key to optimal management of infections caused by this problematic pathogen. The few studies that have examined the genetic variation of large culture collections have employed traditional MLST and indicate a predominantly clonal population structure with infrequent recombination ([@B23]). Prevalence of circulating STs also showed geographical bias ([@B22]; [@B30]; [@B3]). Hence, genetic variation amongst isolates from one region cannot be generalized to another. Here, we determined for the first time using a WGS approach, the relative frequency of endemic STs among 51 Australian *C. glabrata* isolates from two time periods, and verified the applicability of WGS to determine STs, STs by WGS clustered isolates within similar "ST" groupings as *in silico* MLST with good intra-cluster resolution (Figure [1](#F1){ref-type="fig"}).

Sequence typing demonstrated relatively "large" genetic diversity amongst Australian *C. glabrata* isolates, with just under half of the isolates represented by only four STs. The remaining STs, not only represented Australian specific STs (Figures [1](#F1){ref-type="fig"}, [3](#F3){ref-type="fig"}) but suggested an overall diversity within this pathogen that is greater than previously appreciated. In a nationwide Chinese study ([@B30]) of 411 isolates, a "new" ST sequence type was encountered approximately every 11 isolates compared to our study, which observed a "new" ST every 5 isolates. These, and our data emphasize the regional differences, with 75.9% of Chinese isolates comprised of ST7 and ST3 compared to only 25.5% of Australian isolates. Another recent report noted a predominance of ST3 and ST7 (70% isolates) in Korea ([@B12]) whilst in Iran, three STs (ST59, ST74, and ST7) accounted for 50% of isolates further supporting the notion of low intraspecies diversity within *C. glabrata* ([@B3]). Isolates belonging to ST3 have been reported with relative high frequency from Europe and Asia and now, from Australia ([@B22]; this study). The presence of strains with the same ST on different continents demonstrates that clones may have arisen from the same ancestor and disseminated globally followed by local adaptation.

Whilst ST5 isolates were reportedly common in Europe ([@B22]), this ST was not found amongst our Australian isolates nor amongst those from a more recent study of European and US isolates (Tables [1](#T1){ref-type="table"}, [2](#T2){ref-type="table"}). Conversely, isolates of ST7 appear uncommon in Europe and the United States but are more prevalent in Japan, Korea and China ([@B22]; [@B30]; [@B12]; [@B13]). Strains of ST8, ST18, and ST19 were the commonest types in the United States ([@B22]) whereas we identified only one ST18 isolate, no ST19 isolates and two ST8 isolates (from the same patient) in Australia. Broadly, there are more common STs between Australian and Asian isolates than between Australian and US/European isolates likely reflecting the geographical proximity between Asia and Australia. Further studies involving a larger number of *C. glabrata* isolates to test this hypothesis would be of interest. The observed geographic variation among STs highlights the importance of acquiring local data.

MLST analysis of US *C. glabrata* isolates collected over three time periods between 1992--2009 revealed a relatively small number of STs with little genetic differentiation ([@B34]). In the present study, the results indicate that there is no evidence of genomic similarity or ST distribution among the sequences isolated in the two timeframes studied (Figure [2A](#F2){ref-type="fig"}), suggesting that there have been no marked shifts in the present STs. We further found no association between WGS STs and susceptibility or /resistance to fluconazole (Figure [2B](#F2){ref-type="fig"}), consistent with that reported by traditional MLST studies ([@B22]; [@B3]). The phylogenetic tree (Figure [3](#F3){ref-type="fig"}) suggests that both azole and echinocandin resistance may arise at multiple time points, independent of strain clustering. The small numbers of isolates are acknowledged as a study limitation.

Strain typing is essential for epidemiological investigation. MLST has the advantage of providing easily comparable results via internet-accessible databases ([@B22]), but does not adequately capture the breadth of genetic diversity and is not readily available in diagnostic laboratories. The present study has illustrated the utility of WGS to delineate genome variability in *C. glabrata* and importantly offers both superior discriminatory power and convenience. The costs of the two techniques are nearly identical -- approximately AUD 50/sample for MLST and AUD 80/sample for WGS. With decreasing footprint and technological advances, however, cost reduction for WGS is anticipated.

The echinocandin resistance rate of 7.8% (4/51 isolates) in the present study is influenced by sampling bias, being \<2% across Australia ([@B15]), lower than that in the United States ([@B2]; [@B45]). The *FKS1* mutation Ser629Pro (in one isolate) and the mutation *FKS2* Ser663Pro (three isolates) identified are among the most common in *C. glabrata* strains with high-level resistance phenotypes ([@B25]; [@B4]). None of the isolates harbored other well-known mutations that confer echinocandin resistance e.g., R665G, R636S, and F659Y ([@B53]; [@B45]). Conversely, the role of *FKS2* Glu748Gly in isolates WM_18.63 and WM_18.64 in echinocandin resistance remains uncertain as this SNP has not been previously described. Interestingly, the SNP was absent in genomes of all ST8 isolates from other countries in that cluster (Italy2, France9, USA3, USA4, and USA11).

Approximately 25% of *C. glabrata* isolates in our study were fluconazole-resistant, comparable to that in the United States (20--30%) ([@B14]). Genome-wide sequencing revealed mutations in several multidrug resistance transporter genes (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}) (e.g., *CgPDR1* and *CgCDR1*) that are associated with resistance through activation of drug efflux pumps ([@B24]; [@B42]). Although SNPs in these genes were found in both azole-resistant/non wild-type as well as azole-susceptible/wild-type isolates, as previously reported, the alterations were located within the first ∼250 amino acids of Pdr1 in both susceptible and resistant isolates. It is noteworthy that 5/13 fluconazole-resistant isolates had other amino acid substitutions located outside this region of Pdr1 (after the first 250 amino acid positions) (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}) ([@B24]; [@B47]; this study). The reasons for fluconazole resistance in the remaining 8/13 isolates lacking Pdr1 mutations are uncertain. One possibility is that these isolates are petite mutants due to the loss of functional mitochondria, common in *C. glabrata* upon fluconazole exposure ([@B11]; [@B24]). However, effects of specific SNPs in these genes and the potential of petite mutants leading to fluconazole resistance phenotype needs to be confirmed by functional and gene expression analyses, which was beyond the scope of the present study. Through gene deletion studies, it has been recently shown that when functionally active, all of *CDR1, PDR1* and *SNQ2* contribute to high level resistance to azoles ([@B49]). The absence of *ERG11* mutations predominant in other *Candida* species, such as azole-resistant *C. albicans* is also important ([@B37]).

Mutations in the DNA mismatch repair gene *MSH2* are reported to be a genetic driver of multi-drug resistance and about 55% of *C. glabrata* isolates are expected to contain *MSH2* gene mutations. Whilst over 35% of our isolates harbored a mutation in *MSH2*, these were present in both azole-susceptible and azole-resistant (or non-WT) isolates. Hence it is possible that *MSH2* mutations are more a marker of "ST" of *C. glabrata* rather than an indicator of drug resistance, having been linked to isolates of ST16 ([@B28]; [@B21]); similarly, in our study, the mutation Leu269Phe was only present in isolates of ST16 (Supplementary Table [S2](#SM2){ref-type="supplementary-material"}). However, the remaining *MSH2* mutations were found in several STs including two of the novel STs identified herein. Of note, the mutation combination of Val239Leu and Ala942Thr were only identified in ST8.

Limitations of the present study include the relatively small numbers of isolates analyzed, which may have precluded the identification of associations between ST and period of isolation. In addition, the majority of isolates were from blood. However, Lott et al. demonstrated that bloodstream isolates of *C. glabrata* were genetically indistinguishable from those colonizing the host ([@B35]). By using genome-wide information in 33 strains, Carrete et al. inferred the population structure of *C. glabrata* where strains were clustered into highly divergent clades but with the structure suggesting recent global spread of previously isolated populations ([@B13]). WGS with its superior discrimination is well placed to provide additional clues to evolutionary traits in this species.

Conclusion
==========

In conclusion, we have shown the value of a WGS approach for high resolution sequence typing, discovery of novel STs of *C. glabrata*, and the potential to monitor trends in genetic diversity. We envisage useful contribution of our data including that of four novel STs to the global sequence repository. Our results suggest that azole, as well as echinocandin, resistance may arise at multiple time points independent of strain clustering or of STs. WGS assessment for echinocandin resistance has good potential to augment phenotypic susceptibility testing methods. Further study by WGS of *C. glabrata* STs and their evolution over time is warranted.
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